4.6 Article

Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization

Journal

EXPERIMENTAL CELL RESEARCH
Volume 314, Issue 15, Pages 2811-2821

Publisher

ELSEVIER INC
DOI: 10.1016/j.yexcr.2008.06.011

Keywords

RhoB; CK1; actin; phosphorylation

Funding

  1. Engineering and Physical Sciences Research Council [EP/C007247/1] Funding Source: researchfish

Ask authors/readers for more resources

RhoB is a small GTPase implicated in cytoskeletal organization, EGF receptor trafficking and cell transformation, It is an immediate-early gene, regulated at many levels of its biosynthetic pathway. Herein we show that the serine/threonine protein kinase CK1 phosphorylates RhoB in vitro but not RhoA or RhoC. With the use of specific CK1 inhibitors, IC261 and D4476, we show that the kinase phosphorylates also RhoB in HeLa cells. Mass spectrometry analysis demonstrates that RhoB is monophosphorylated by CK1, in its C-terminal end, on serine 185. The substitution of Ser185 by Ala dramatically inhibited the phosphorylation of RhoB in cultured cells. Lastly we show that the inhibition of CK1 activates RhoB and promotes RhoB dependent actin fiber formation and EGF-R level. Our data provide the first demonstration of RhoB phosphorylation and indicate that this post-translational maturation would be a novel critical mechanism to control the RhoB functions. (c) 2008 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, Research & Experimental

Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

Emilie Bousquet Mur, Sara Bernardo, Laura Papon, Maicol Mancini, Eric Fabbrizio, Marion Goussard, Irene Ferrer, Anais Giry, Xavier Quantin, Jean-Louis Pujol, Olivier Calvayrac, Herwig P. Moll, Yael Glasson, Nelly Pirot, Andrei Turtoi, Marta Canamero, Kwok-Kin Wong, Yosef Yarden, Emilio Casanova, Jean-Charles Soria, Jacques Colinge, Christian W. Siebel, Julien Mazieres, Gilles Favre, Luis Paz-Ares, Antonio Maraver

JOURNAL OF CLINICAL INVESTIGATION (2020)

Editorial Material Medicine, Research & Experimental

Finding mutations of interest in circulating tumor DNA helps predict immunotherapy response in lung cancer

Nicolas Guibert, Anne Pradines, Gilles Favre, Julien Mazieres

M S-MEDECINE SCIENCES (2020)

Article Immunology

Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer

Chloe Laplagne, Sarah Meddour, Sarah Figarol, Marie Michelas, Olivier Calvayrac, Gilles Favre, Camille Laurent, Jean-Jacques Fournie, Stephanie Cabantous, Mary Poupot

FRONTIERS IN IMMUNOLOGY (2020)

Meeting Abstract Oncology

ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor plus palbociclib (AI plus P) for metastatic breast cancer (MBC) in the PADA-1 trial

J-S. Frenel, F. Dalenc, B. Pistilli, T. de la Motte Rouge, C. Levy, M-A. Mouret-Reynier, A-C. Hardy-Bessard, N. Bonichon-Lamichhane, C. Greilsamer, V. Delecroix, S. Nguyen, F. Berger, S. Everhard, J. Lemonnier, D. Loirat, C. Callens, A. Pradines, T. Bachelot, S. Delaloge, F. C. Bidard

ANNALS OF ONCOLOGY (2020)

Meeting Abstract Oncology

Oligometastatic breast cancer incidence and clinical presentation at diagnosis: About 131 cases

J. L. Lacaze, C. Chira, G. Glemarec, R. Aziza, E. De Maio, F. Izar, E. Jouve, C. Massabeau, A. Pradines, G. Selmes, M. Ung, S. Zerdoud, F. Dalenc

ANNALS OF ONCOLOGY (2020)

Article Oncology

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer

Sandra Ortiz-Cuaran, Laura Mezquita, Aurelie Swalduz, Mihalea Aldea, Julien Mazieres, Camille Leonce, Cecile Jovelet, Anne Pradines, Virginie Avrillon, Washington R. Chumbi Flores, Ludovic Lacroix, Yohann Loriot, Virginie Westeel, Maud Ngo-Camus, Claire Tissot, Christine Raynaud, Radj Gervais, Etienne Brain, Isabelle Monnet, Etienne Giroux Leprieur, Caroline Caramella, Celine Mahier-Ait Oukhatar, Natalie Hoog-Labouret, Frank de Kievit, Karen Howarth, Clive Morris, Emma Green, Luc Friboulet, Sylvie Chabaud, Jean-Francois Guichou, Maurice Perol, Benjamin Besse, Jean-Yves Blay, Pierre Saintigny, David Planchard

CLINICAL CANCER RESEARCH (2020)

Review Cell Biology

Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!

Lucile Durin, Anne Pradines, Celine Basset, Bryan Ulrich, Laura Keller, Vincent Dongay, Gilles Favre, Julien Mazieres, Nicolas Guibert

CELLS (2020)

Article Pathology

Minimal Residual Disease Monitoring Using a 3′ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR

Cathy Quelen, David Grand, Emeline Sarot, Laurence Brugieres, David Sibon, Anne Pradines, Camille Laurent, Pierre Brousset, Laurence Lamant

Summary: In ALK-positive anaplastic large-cell lymphomas, real-time quantitative PCR can identify high-risk patients, but the current technique designed for patients with the most common NPM1-ALK translocation has reproducibility issues among different laboratories.

JOURNAL OF MOLECULAR DIAGNOSTICS (2021)

Review Oncology

Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges

Bryan Ulrich, Anne Pradines, Julien Mazieres, Nicolas Guibert

Summary: Circulating tumor DNA is a novel biomarker that shows potential in predicting cancer relapse and guiding adjuvant therapies. In patients with localized disease, ctDNA kinetics is considered a highly sensitive and specific marker for relapse. Further research is needed to explore the full potential of ctDNA as a tool for personalized treatment in non-small-cell lung cancer.

CANCERS (2021)

Article Oncology

Diagnosis, biology and epidemiology of oligometastatic breast cancer

Jean-Louis Lacaze, Richard Aziza, Ciprian Chira, Eleonora De Maio, Francoise Izar, Eva Jouve, Carole Massabeau, Anne Pradines, Gabrielle Selmes, Mony Ung, Slimane Zerdoud, Florence Dalenc

Summary: Oligometastatic breast cancer (OMBC) lacks a standardized treatment strategy, with limited information provided by existing literature. Research on OMBC biological characteristics suggests a focus on circulating tumor cell counts, as well as development of studies on microRNAs, circulating tumor DNA, and genomic alterations.

BREAST (2021)

Review Oncology

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

Celia Delahaye, Sarah Figarol, Anne Pradines, Gilles Favre, Julien Mazieres, Olivier Calvayrac

Summary: The article discusses the benefits and limitations of more effective treatments for lung cancer patients, as well as the emergence of resistance. It emphasizes the importance of understanding the mechanisms underlying DTP survival for developing therapeutic strategies.

CANCERS (2022)

Meeting Abstract Oncology

Characterization of ESR1 mutations at metastatic relapse and outcome under first line aromatase inhibitor and palbociclib in the PADA-1 trial.

Anne Pradines, Celine Callens, Aurelia Doussine, Ivan Bieche, Jerome Lemonnier, Marjorie Mauduit, Thomas Bachelot, Florence Dalenc, Alain Lortholary, Barbara Pistilli, Thibault De la Motte Rouge, Renaud Sabatier, Jean-Marc Ferrero, Sylvain Ladoire, Frederique Berger, Francois-Clement Bidard

CANCER RESEARCH (2021)

Meeting Abstract Oncology

Prognostic impact of ESR1 mutations in ER+HER2-MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

Francois Clement Bidard, Celine Callens, Florence Dalenc, Barbara Pistilli, Thibault De La Motte Rouge, Florian Clatot, Veronique D'hondt, Luis Teixeira, Helene Vegas, Sibille Everhard, Jerome Lemonnier, Ivan Bieche, Anne Pradines, Jean FranCois Paitel, Dominique Spaeth, Isabelle Moullet, Jean-Yves Pierga, Frederique Berger, Anne-Claire Hardy-Bessard, Thomas Bachelot

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Oncology

Value of PAM50 risk of recurrence score in patients with HR positive HER2 negative early breast cancer and intermediate risk: A single cancer center institution prospective observational study

Vincent Nicolai, Julia Gilhodes, Jean Louis Lacaze, Mony Ung, Eleonora De Maio, Raphaelle Duprez-Paumier, Charlotte Vaysse, Thomas Filleron, Eva Jouve, Gabrielles Selmes, Camille Franchet, Carole Massabeau, Cyprian Chira, Francoise Izar, Henri Roche, Anne Pradines, Florence Dalenc

CANCER RESEARCH (2020)

No Data Available